The optimal threshold of controlled attenuation parameter (CAP) for the detection of hepatic steatosis using both M and XL probe is unknown in nonalcoholic fatty liver disease (NAFLD). Magnetic resonance imaging proton density fat fraction (MRI-PDFF) is an accurate and precise method of detecting the presence of hepatic steatosis that is superior to CAP. Thus, the aim of this study was to evaluate the diagnostic accuracy and optimal threshold of CAP for the detection of hepatic steatosis as defined by MRI-PDFF 5%. This prospective cross-sectional study included 119 adults (59% women) with and without NAFLD who underwent MRI-PDFF and CAP using either M or XL probe when indicated within a 6-month period at the NAFLD Research Center, University of California, San Diego. The mean ( 6 standard deviation) age and body mass index were 52.4 (615. .85]; P 5 0.0117), and these differences were statistically and clinically significant. Conclusion: The cut-point of CAP for presence of hepatic steatosis (MRI-PDFF 5%) was 288 dB/m. The diagnostic accuracy of CAP for the detection of hepatic steatosis is more reliable when the IQR of CAP is <30 dB/m. These data have implications for the clinical use of CAP in the assessment of NAFLD. (HEPATOLOGY 2018;67:1348-1359 N onalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide. (1, 2) In the United States, NAFLD is estimated to affect approximately one-third of the adult population, and its prevalence is strongly associated with obesity, type 2 diabetes, and metabolic syndrome. (1, 3, 4) NAFLD is currently the second leading etiology for the indication of liver transplantations in the United States, (5) (6) (7) and yet early stage of NAFLD, such as simple hepatic steatosis, remains broadly underdiagnosed, although it can potentially progress to nonalcoholic steatohepatitis, Abbreviations: AUROC, area under the receiver operator characteristic curve; BMI, body mass index; CAP, controlled attenuation parameter; CI, confidence interval; IQR, interquartile range; MRI, magnetic resonance imaging; MRI-PDFF, magnetic resonance imaging proton density fat fraction; NAFLD, nonalcoholic fatty liver disease; ROC, receiver operator characteristic curve; UCSD, University of California at San Diego.
, respectively. The prevalence of NAFLD (MRI-PDFF 5%) and MRI-PDFF 10% was 70.6% and 47.1%, respectively. The area under the receiver operating characteristic (AUROC) of CAP for the detection of MRI-PDFF 5% was 0.80 (95% confidence interval [CI] , 0.70-0.90) at the cut-point of 288 dB/m and of MRI-PDFF 10% was 0.87 (95% CI, 0.80-0.94) at the cut-point of 306 dB/m. When stratified by the interquartile range (IQR) of CAP, we observed that an IQR below the median (30 dB/m) had a robust AUROC compared with an IQR above the median (0.92 [95% CI, 0.85-1.00] versus 0.70 [95% CI, 0.56-0.85]; P 5 0.0117), and these differences were statistically and clinically significant. Conclusion: The cut-point of CAP for presence of hepatic steatosis (MRI-PDFF 5%) was 288 dB/m. The diagnostic accuracy of CAP for the detection of hepatic steatosis is more reliable when the IQR of CAP is <30 dB/m. These data have implications for the clinical use of CAP in the assessment of NAFLD. (HEPATOLOGY 2018; 67:1348 -1359 N onalcoholic fatty liver disease (NAFLD) is being recognized as one of the most prevalent causes of chronic liver disease worldwide. (1, 2) In the United States, NAFLD is estimated to affect approximately one-third of the adult population, and its prevalence is strongly associated with obesity, type 2 diabetes, and metabolic syndrome. (1, 3, 4) NAFLD is currently the second leading etiology for the indication of liver transplantations in the United States, (5) (6) (7) and yet early stage of NAFLD, such as simple hepatic steatosis, remains broadly underdiagnosed, although it can potentially progress to nonalcoholic steatohepatitis, leading to liver fibrosis, cirrhosis, and hepatocellular carcinoma. (8, 9) Although liver biopsy is considered as the reference method for the diagnosis of NAFLD, it encounters important limitations. Its accuracy has been questioned due to sampling errors and its interpretation and quantitative scoring is limited by significant inter-and intra-observer variability. (10) (11) (12) (13) (14) (15) In addition, liver biopsy is an expensive and invasive procedure which limits its use for the screening of population. (12) Thus, there is an increasing interest in developing noninvasive imaging techniques that can clinically assess hepatic steatosis in NAFLD. Although conventional ultrasonography is widely used as a first-line assessment of hepatic steatosis, it is limited by a lack of quantitative accuracy and is operator-dependent, (16, 17) and computerized tomography is limited by radiation exposure and inaccurate quantification of steatosis. (18) Magnetic resonance imaging (MRI) techniques such as magnetic resonance spectroscopy have emerged as leading noninvasive modalities for steatosis quantification in NAFLD in terms of sensitivity, specificity and reliability. (18, 19) MRI that measures the proton density fat fraction (MRI-PDFF) has been proven to correlate well with magnetic resonance spectroscopy (20, 21) and histology-proven steatosis grade from contemporaneous liver biopsies. (22) (23) (24) (25) However, similar to liver biopsies, MRI is expensive and not routinely accessible.
The controlled attenuation parameter (CAP) is a novel technique based on the properties of ultrasonic signals developed to quantify ultrasound attenuation during measurement of liver stiffness vibration controlled elastography acquired by the FibroScan. (26) Although CAP is less accurate than MRI-PDFF in detecting all grades of hepatic steatosis, (27, 28) CAP has been shown to correlate with histological grade of hepatic steatosis in several studies. (26, (29) (30) (31) (32) Moreover, CAP allows a rapid, noninvasive, bedside assessment of hepatic steatosis, and it is less expensive and more accessible than MRI. However, the use of CAP for the diagnosis of NAFLD in routine clinical practice is limited due to the lack of optimal threshold of CAP for the detection of hepatic steatosis and the absence of indicator of the quality of CAP measurements. Recently, Karlas et al. (31) performed an individual patient meta-analysis on CAP accuracy for the grading of hepatic steatosis to better define a relevant threshold of CAP for the stage of hepatic steatosis. However, this study included patients with heterogeneous etiology of chronic liver diseases, mainly viral hepatitis and a minority with NAFLD. Furthermore, CAP was exclusively measured using M probe, the use of which is limited in obese patients due to a high failure rate, (33) yet obesity is a frequent characteristic of NAFLD patients. The use of the XL probe equipped with CAP has been shown to reduce the failure rate in obese patients providing improvement in the use of CAP for the diagnosis of NAFLD. (34, 35) Studies including NAFLD patients have reported different thresholds of CAP using M and XL probe for the grade of steatosis using liver biopsy as reference.
a head-to-head comparison with another quantitative measure of hepatic steatosis; the present study fills that gap in knowledge.
Using a well-characterized, prospective cohort of American adults with NAFLD and non-NAFLD controls, we conducted a cross-sectional analysis to evaluate the diagnostic accuracy and the optimal threshold of CAP using M and XL probes for the detection of hepatic steatosis as defined by MRI-PDFF 5%.
Patients and Methods

STUDY PARTICIPANTS AND DESIGN
This was a cross-sectional analysis of participants derived consecutively from a prospective cohort aimed at assessing the diagnostic accuracy and optimal threshold of CAP to diagnose hepatic steatosis (defined as MRI-PDFF 5%) and non-NAFLD controls (defined as MRI-PDFF < 5%). We followed the Standards for Reporting of Diagnostic Accuracy guidelines (Supporting Table S1 ; see the Supporting Information for further details).
Study participants were recruited from the NAFLD Research Center at the University of California, San Diego (UCSD), between July 2014 and May 2017. A total of 157 potential eligible participants were screened, 156 of whom were deemed eligible for the study; of these, 119 participants complied with the study protocol and underwent MRI-PDFF and CAP assessment within a 6-month period (Supporting Fig.  S1 ). All participants underwent a careful evaluation for other causes of hepatic steatosis and liver disease and were invited for a clinical research visit with standardized history, physical and anthropometric examination, fasting biochemical testing, transient elastography, and CAP assessment at the UCSD NAFLD Research Center, (20, 21, 27, (37) (38) (39) (40) (41) (42) advanced MRI-based phenotyping at the UCSD MR3T Research Laboratory. This study was compliant with the Health Insurance Portability and Accountability Act and was approved by the UCSD Institutional Review Board. Informed written consent was obtained from all participants.
INCLUSION AND EXCLUSION CRITERIA
Inclusion criteria were as follows: at least 18 years of age, willing and able to complete all procedures and observations specified in the protocol, fully informed, and had signed the Informed Consent/Assent and Health Insurance Portability and Accountability Act provisions.
Exclusion criteria were as follows: history of significant alcohol intake within 2 years of recruitment (14 drinks/week for men or 7 drinks/week for women); any evidence of secondary causes of hepatic steatosis including nutritional, iatrogenic, or infectious etiology or human immunodeficiency virus infection; evidence of liver diseases other than NAFLD, including viral hepatitis (screened by positive serum hepatitis B surface antigen and hepatitis C RNA assays), autoimmune hepatitis, and genetic or acquired disorders (e.g., hemochromatosis, Wilson disease, glycogen storage disease, alpha-1 antitrypsin deficiency, and cholestatic or vascular liver disease); evidence of decompensated liver disease (defined as Child-Pugh score > 7 points); active substance use; major systemic illnesses; contraindications to MRI; pregnant or trying to be pregnant; or any other conditions believed by the principal investigator to affect a patient's competence, compliance, or completion of the study.
CLINICAL RESEARCH EVALUATION
All patients underwent a standardized clinical evaluation, detailed history, anthropometric examination, and fasting biochemical tests at the UCSD NAFLD Research Center. Detailed information from history and anthropometric examination included age, sex, height, weight, body mass index (BMI), and ethnicity; vital signs were collected by a trained clinical investigator. Alcohol consumption was documented in prior clinical visit and confirmed in the research clinic using the Alcohol Use Disorders Identifications Test and the Skinner questionnaire. Other causes of liver diseases and secondary causes of hepatic steatosis such as steatogenic medications were ruled out systematically using history and biochemical tests. Biochemical tests included aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase, total bilirubin, direct bilirubin, albumin, hemoglobin A1c, fasting glucose, insulin, prothrombin time, international normalized ratio, fasting lipid panel, platelet count, and ferritin.
OUTCOME MEASURES
The primary outcome was the presence of hepatic steatosis defined as MRI-PDFF 5%. The secondary outcome was the detection of hepatic fat content 10% defined as MRI-PDFF 10%, because this threshold has been used in several therapeutic trials as inclusion criteria.
TRANSIENT ELASTOGRAPHY AND CAP MEASUREMENT
Transient elastography was performed by a trained technician, blinded to clinical and MRI results, using the FibroScan 502 Touch model (M Probe, XL Probe; Echosens, Paris, France). Detailed methods have been described previously. (43, 44) Briefly, transient elastography measurement was obtained in the supine position with the right arm fully adducted by scanning the area of abdomen at the location of the right liver lobe during a 10-second breath hold. Participants were asked to fast at least 3 hours before the examination. The procedure included a minimum of 10 measurements to determine the median valid liver stiffness measurements (in kilopascals) and the interquartile range (IQR). According to the manufacturer's protocol, all patients were first scanned using the M probe (3.5 MHz) and when indicated by the equipment upon initial assessment, patients were rescanned using the XL probe (2.5 MHz). The CAP value in dB/m was simultaneously measured for the assessment of liver steatosis measurements, colocalized to the valid liver stiffness measurements. All CAP data were collected prospectively. Each participant underwent two consecutive readings of LSM and CAP by the same FibroScan. Unreliable liver stiffness was defined as success rate (ratio of the number of successful measurements to the total number of acquisitions) < 60% and/or number of valid measurements <10 and/or IQR/ median > 30%. (45) 
MRI-PDFF
Advanced MRI based phenotyping was performed at the UCSD MR3T Research Laboratory using a 3T research scanner (GE Signa EXCITE HDxt; GE Healthcare, Waukesha, WI) with all participants in the supine position. MRI-PDFF was used to measure hepatic steatosis defined as MRI-PDFF 5%. The details of the MRI protocol have been described previously. (22, 23, 46, 47) The median time between MRI-PDFF and CAP was 8 days. The image analysts were blinded to all clinical and biochemical data.
RATIONALE FOR USING MRI-PDFF FOR HEPATIC STEATOSIS QUANTIFICATION AS GOLD STANDARD
MRI-PDFF was used as a gold standard for the following reasons. First, to provide a relevant quantitative threshold of CAP for the detection of hepatic steatosis, measurement using a quantitative modality should be used. MRI-PDFF is a quantitative method that has been shown to be a highly precise, accurate, and reproducible noninvasive biomarker for the quantification of liver fat content. (48, 49) It has been proven to correlate well with magnetic resonance spectroscopy (r (2) 5 0.99, P < 0.001) (20, 21) and histology-proven steatosis grade from contemporaneous liver biopsies. (22) (23) (24) (25) In addition, MRI-PDFF has been demonstrated to be superior to ultrasound, computed tomography, and CAP for quantification of liver fat content. (19, 27) Second, in the future, many therapeutic trials in NAFLD will require a liver biopsy, which is an invasive and expensive procedure. MRI-PDFF is similarly expensive, thus an optimal threshold of CAP to approximate MRI-PDFF 5% for the screening of patients with and without NAFLD would reduce the cost of therapeutic trials. In addition, several trials used MRI-PDFF 10% as inclusion criteria and thus, an optimal threshold of CAP to approximate MRI-PDFF 10% was chosen as a secondary outcome. Third, to be able to assess the diagnostic accuracy of CAP for the detection of hepatic steatosis as defined by MRI-PDFF 5%, participants with and without NAFLD are needed, and it would be unethical to perform a liver biopsy in participants who do not have a clinical indication of performing a liver biopsy.
STATISTICAL ANALYSES
Patients' demographic data, laboratory, and imaging data were summarized using the mean and standard deviation for continuous variables or median and IQR and with numbers and percentages for categorical variables. The mean and frequency were compared using an independent samples t test, Wilcoxon rank sum test, chi-squared test, or Fisher's exact test where appropriate. The Kruskal-Wallis test was used to compare CAP and different category of hepatic fat content assessed with MRI-PDFF. Abbreviations: ALT, alanine aminotransferase; APRI, AST to platelet ratio; AST, aspartate aminotransferase; BMI, body mass index; CAP, controlled attenuation parameter; GGT, gamma-glutamyl transpeptidase; HDL, high-density lipoprotein; IQR, interquartile range; LDL, low-density lipoprotein; MRI-PDFF, magnetic resonance imaging proton-density fat fraction; NAFLD, nonalcoholic fatty liver disease. Continuous variables are expressed as the mean (standard deviation) or median unless otherwise noted as the median (IQR) or n (%). Success rate was defined as the ratio of the number of valid measurements to the total number of measurements. *Boldface type indicates a significant P value (P < 0.05). † Obesity was defined as BMI 30 kg/m 2 . ‡ Unreliable liver stiffness was defined as success rate <60% and/or number of valid measurement <10 and/or IQR/median > 30%. (45) The P value was determined by comparing the characteristics of patients without NAFLD (MRI-PDFF<5%) and with NAFLD (MRI-PDFF 5%) using an independent samples t test, Wilcoxon two-sample test, chi-squared test, or Fisher's exact test as appropriate.
Main Analyses
Receiver operating characteristic (ROC) curve analyses were used to assess the diagnostic accuracy of CAP for the detection of hepatic steatosis (MRI-PDFF 5%) and of hepatic fat content 10%. For each ROC analysis, the area under the ROC curve (AUROC), the optimal thresholds, and the following performance parameters were calculated: sensitivity, specificity, positive predictive value, and negative predictive value. The optimal threshold of each modality was determined using the Youden index. (50) Sample Size Estimation Given the previously described superiority of MRI-PDFF for the detection of hepatic steatosis in NAFLD biopsy-proven cohort, (27) an AUROC of CAP of 0.85 (0.75-0.96) for the detection of hepatic steatosis, and a correlation between MRI-PDFF and CAP approximately of 0.50, a projected sample size of 102 people is needed to assess the diagnostic accuracy of CAP for the detection of hepatic steatosis using MRI-PDFF as a gold standard with an alpha of 0.05 and a power of 0.80.
Sensitivity Analyses
Sensitivity analyses were conducted to further assess the impact of covariates on the accuracy of CAP for detection of hepatic steatosis as defined by MRI-PDFF 5%. The AUROC of CAP was compared using the method described by Hanley and McNeil. (51) All statistical analyses were performed using SAS 9.4 (SAS Institute, Cary, NC) or SPSS (IBM, Chicago, IL). A two-tailed P value 0.05 was considered statistically significant.
Results
BASELINE CHARACTERISTICS
In this prospective study, 119 participants (female, n 5 70; male, n 5 49) with MRI-PDFF and CAP were enrolled consecutively. The mean ( 6 standard deviation) age and BMI were 52.4 (615.2) years and 29.9 (65.5) kg/m 2 , respectively. Baseline cohort characteristics are summarized in Table 1 . CAP were assessed using either M probe (n 5 82, 68.9%) or XL probe (n 5 37, 31.1%) when appropriate. The prevalence of NAFLD (MRI-PDFF 5%) and MRI-PDFF 10% was 70.6% (n 5 84) and 47.1% (n 5 56), respectively. A total of 156 patients were eligible for the study, but 22 patients were excluded because CAP was not performed and 15 patients were excluded because MRI-PDFF was not performed (Supporting Fig. S1 ).
DIAGNOSTIC ACCURACY OF CAP FOR THE DETECTION OF HEPATIC STEATOSIS (MRI-PDFF 5%)
The distribution of CAP measurements across different category of hepatic fat content assessed with MRI-PDFF is illustrated in Figure 1 . The AUROC of CAP for the detection of hepatic steatosis (MRI-PDFF 5%) was 0.80 (95% confidence interval [CI], 0.70-0.90) at the cut-point of 288 dB/m (Fig. 2A) . The sensitivity, specificity, positive predictive value, and negative predictive value of CAP for the detection of hepatic steatosis (MRI-PDFF 5%) were 75.0%, 77.1%, 88.7%, 56.2%, respectively (Table 2) .
DIAGNOSTIC ACCURACY OF CAP FOR THE DETECTION OF HEPATIC FAT CONTENT 10% (MRI-PDFF 10%)
The AUROC of CAP for the detection of hepatic fat content 10% (MRI-PDFF 10%) was 0.87 (95% CI, 0.80-0.94) at the cut-point of 306 dB/m (Fig. 2B) . The sensitivity, specificity, positive predictive value, and negative predictive value of CAP for the detection of hepatic fat content 10% (MRI-PDFF 10%) were 78.6%, 82.5%, 80.0%, 81.2%, respectively (Table 2 ). Additional analysis assessing the diagnostic accuracy of CAP for the detection of hepatic fat content 15% (MRI-PDFF 15%) and hepatic fat content 20% (MRI-PDFF 20%) are provided in Supporting Table S2 .
SENSITIVITY ANALYSES OF THE PERFORMANCE OF CAP FOR THE DETECTION OF HEPATIC STEATOSIS
When stratified by M probe or XL probe, CAP measurements were significantly higher using XL probe compared with M probe in the lower grade of hepatic fat content with a mean ( 6 standard deviation) of 300.14 (635.14) dB/m versus 230.25 (657.7) dB/ m (P 5 0.005), respectively, when MRI-PDFF was below 5%; and 295.0 (647.00) dB/m versus 254.47 (646.60) dB/m (P 5 0.034), respectively, when MRI-PDFF was between 5% and 10% (Fig. 3 , Supporting Table S3 ).
When stratified by IQR of CAP, the direct comparison of the AUROC of CAP for the detection of hepatic steatosis (MRI-PDFF 5%) using the Hanley and McNeil test revealed that CAP measurement with IQR of CAP below the median (30 dB/m) was significantly more accurate than CAP measurement with IQR of CAP above the median (30 dB/m) for the detection of hepatic steatosis (MRI-PDFF 5%) with an AUROC of 0.92 (95% CI, 0.85-1.00) versus 0.70 Abbreviations: AUROC, area under the receiver operator characteristic curve; CAP, controlled attenuation parameter; CI, confidence interval; MRI-PDFF, magnetic resonance imaging proton-density fat fraction; NPV, negative predictive value; PPV, positive predictive value.
FIG. 2.
Diagnostic accuracy of CAP for the detection of hepatic steatosis. ROC and AUROC (A) for the detection of hepatic steatosis defined by MRI-PDFF 5% and (B) for the detection of hepatic fat content 10% defined as MRI-PDFF 10%.
(95% CI, 0.56-0.85) (P 5 0.0117) (Fig. 4) . In the subgroup of individuals with IQR of CAP <30 dB/m, there was no significant difference in the performance of CAP between unadjusted and adjusted model when either BMI or type 2 diabetes status was included in the models. The optimal strategy for the screening of NAFLD using CAP and IQR of CAP as validity criteria is detailed in Figure 5 .
Discussion
MAIN FINDINGS
Using a well-characterized, prospective cohort of American adults with and without NAFLD, this study demonstrates that the optimal threshold of CAP for the detection of hepatic steatosis as defined by MRI-PDFF 5% is 288 dB/m with a good diagnostic accuracy (AUROC, 0.80; 95% CI, 0.70-0.90). Furthermore, the secondary analysis revealed that the optimal threshold of CAP for the detection of hepatic fat content 10% (MRI-PDFF 10%) is 306 dB/m with an AUROC of 0.87 (95% CI, 0.80-0.94), which could be integrated in future clinical trial design as inclusion criteria. The key finding of this study is to provide estimates of the diagnostic accuracy and optimum thresholds of CAP measurements, using M or XL probes, for the detection of hepatic steatosis by an accurate and quantitative standard using MRI-PDFF in a Western population with NAFLD and non-NAFLD controls. These data have important implications for the clinical use of CAP in the assessment of NAFLD and would help develop an optimal clinical approach for noninvasive diagnosis of NAFLD. Furthermore, CAP may have use in longitudinal followup of anti-steatosis therapeutic interventions in clinical routine practice. In addition, this study demonstrates that the diagnostic accuracy of CAP for the detection of hepatic steatosis is more reliable when the IQR of CAP is <30 dB/m, providing a reliable quality indicator that would help clinicians interpret CAP measurements. Ultimately, the use of these optimal thresholds for the quantitative diagnosis of hepatic fat may modify the clinical trial design for the treatment of NAFLD and reduce costs by reducing screen failure rates for the trials that use an MRI-PDFF of 10% or higher for inclusion. In the future, patients with certain CAP values may only move forward for MRI-PDFF assessment in these clinical trials, thereby reducing the number of MRI scans needed to enroll patients in a trial. However, further studies are needed to determine the clinical relevance and cost-effectiveness of CAP for the diagnosis of hepatic steatosis in NAFLD.
IN CONTEXT WITH PUBLISHED LITERATURE
This is the first prospective study to assess the optimal threshold of CAP for the diagnosis of hepatic   FIG. 3 . Higher CAP value using XL probe compared with M probe when MRI-PDFF < 10%. CAP measurements and standard deviation are presented using M probe (white bar) and XL probe (dotted bar) stratified by hepatic fat content assessed by MRI-PDFF. CAP measurements were significantly higher using XL probe compared with M probe in the lower grade of hepatic fat content. P values were determined using an independent two-tailed t test. steatosis using M and XL probe in a in a wellcharacterized cohort of American adults with NAFLD and non-NAFLD controls using advanced MRI-PDFF as the gold standard. This study also provides the first estimates of the diagnostic accuracy and optimal threshold of CAP for the detection of hepatic fat content 10%, which is used as inclusion criteria in therapeutic trials (NCT02912260, NCT02781584). We report a good diagnostic accuracy of CAP for the detection of hepatic steatosis in NAFLD with an AUROC of 0.80 (95% CI, 0.70-0.90) consistent with previous studies. (26, (29) (30) (31) (32) Furthermore, we found that an IQR of CAP < 30 dB/m is a good criterion for CAP measurement, which is also consistent with a recent study by Wong et al. (32) showing the validity of CAP for the diagnosis of fatty liver is lower if the IQR of CAP is 40 dB/m using M probe in a cohort of patients with different liver diseases.
In a recent study, Karlas et al. (31) proposed an optimal threshold of CAP for the detection of histological steatosis grade above S0 of 248 dB/m (237-261) based on an individual patient meta-analysis including heterogeneous etiology of chronic liver disease. Interestingly, the authors have identified that the etiology of the liver disease, in addition to features highly associated with NAFLD (such as diabetes and BMI), need FIG. 5 . Optimal strategy for the screening of NAFLD using CAP measurements and its IQR as validity criteria. CAP measurements are considered valid when the IQR of CAP is below 30 dB/m and 10 valid measurements are achieved. If the valid CAP measurement is below the optimal threshold, the patient is considered as non-NAFLD.
FIG. 4.
The diagnostic accuracy of CAP increase when IQR of CAP is <30 dB/m. The AUROC of CAP and 95% CI for the detection of hepatic steatosis defined by MRI-PDFF 5% was significantly higher when IQR of CAP was below the median (30 dB/m) (n 5 60) compared with the AUROC of CAP when IQR of CAP (n 5 59) was above the median (P 5 0.017) determined using the method by Hanley and McNeil. consideration when interpreting CAP. The latter observation highlights the utmost need to assess CAP in the setting of well-characterized NAFLD cohorts. Indeed, the demographical characteristics of our cohort, such as higher BMI (29.9 6 5.5 kg/m 2 ) and higher prevalence of type 2 diabetes, may have reflected a more accurate assessment of the diagnostic performances and thresholds of CAP in a Western population with NAFLD and non-NAFLD controls. Therefore, these covariates may at least partially account for the different threshold found in our study and this metaanalysis: 288 dB/m versus 248 dB/m, respectively.
Fewer studies including small cohorts have assessed the diagnostic accuracy of CAP using XL probe. (34, 35, 44) The sensitivity analyses reveal that CAP measurements were significantly higher using XL probe compared with M probe in the lower grade of hepatic fat content. Similarly, Chan et al. (35) have shown significant higher value of CAP using XL probe compared with M probe in an Asian NAFLD cohort.
Likewise, Vuppalanchi et al. (36) reported recently that patients with NAFLD in a multicenter setting had significantly higher CAP values when measured with XL probe compared with M probe in an adjusted model for BMI. In this study, only 4.2% of the total cohort did not have NAFLD, as opposed to 29.4% in the current study. In addition, liver biopsy was used as the reference standard, and only a minority of patients had grade 0 steatosis (which would equate with an MRI-PDFF < 5%). Therefore, our study is complimentary to this previous study and provides a more robust assessment of CAP for detection of presence of hepatic steatosis at a threshold of MRI-PDFF of 5%. We believe that the reference standard that is required to establish the optimal threshold of CAP to detect the presence of hepatic steatosis in clinical practice would have to be quantitative, reproducible, and valid across the entire dynamic range of liver fat content (liver fat content typically ranges between 0.2% and 50% on magnetic resonance spectroscopy) rather than a subjective estimate of liver fat on an ordinal scale using histologic grade of steatosis.
Although direct comparisons of the performance of CAP using XL probe compared with an M probe have shown similar diagnostic accuracy, (34, 35) further studies using both probes on the same patients are needed to compare CAP measurement using M and XL probe.
Hepatic steatosis is an important clinical feature in NAFLD that can progress to nonalcoholic steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. (8, 9) Therefore, early diagnosis and screening of hepatic steatosis before the progression to nonalcoholic steatohepatitis and severe liver fibrosis may benefit patients at risk of NAFLD. Contrary to viral hepatitis, the impact of hepatic steatosis on accelerating the disease progression to fibrosis and cirrhosis is unclear in NAFLD. Future longitudinal studies designed to determine the prognostic significance of hepatic steatosis in long-term outcomes are needed.
STRENGTHS AND LIMITATIONS
There are several notable strengths of this study, including the prospectively well-characterized recruited cohort by experienced investigators at a dedicated research center that specializes in both clinical and radiologic research of NAFLD. All participants underwent a systematic and standardized liver disease assessment to exclude for other causes of liver disease before inclusion in the study, in addition to a detailed advanced MRI examination of the liver.
However, we acknowledge the following limitations. This was a single-center study conducted at a highly specialized tertiary care center using advanced MRI techniques that may not be available in other clinical centers; therefore, the generalizability of these findings in other clinical settings is unknown. In addition, the cross-sectional design of the study did not allow the assessment of CAP for monitoring longitudinal changes in hepatic fat content. Liver biopsy was not performed in this study, because the study was designed to assess the optimal threshold of CAP, which is a quantitative biomarker for the detection of hepatic steatosis, and therefore a quantitative modality should be used as a gold standard. We used the most accurate noninvasive quantitative modality, which has emerged as a novel standardized biomarker for assessing hepatic steatosis. (52) MRI-PDFF has been proven to correlate well with magnetic resonance spectroscopy (20, 21) and histology-proven steatosis grade. (22) (23) (24) Additionally, MRI-PDFF performance has been reported to be higher than histology in quantifying changes in steatosis in longitudinal studies. (20, 48) 
IMPLICATIONS FOR CLINICAL CARE AND FUTURE RESEARCH
Using a prospective study, we confirmed the good diagnostic accuracy of CAP for the detection of hepatic steatosis as defined by MRI-PDFF 5%, and we provided an optimal threshold of 288 dB/m using XL probe when appropriate in an American cohort of well-characterized individuals with NAFLD and non-NAFLD controls. The use of this new threshold, which is higher than the previous threshold, is more accurate and would decrease the screen failure rate in clinical trials. Furthermore, the use of this optimal threshold may enable the use of CAP for noninvasive diagnosis of NAFLD in routine clinical practice. Future studies are necessary to assess the clinical use of CAP for diagnosis of hepatic steatosis in a multicenter, longitudinal design, both in observational and intervention studies. The cost-effectiveness of using CAP versus other available modalities must also be evaluated to develop optimal diagnostic strategies for diagnosing NAFLD.
